Leadership Transition: Concord Biotech CFO Lalit Sethi To Retire Early

Inside the announcement  
Lalit Sethi submitted his formal retirement notice on December 8, 2025. The company acknowledged his contributions, particularly in strengthening Concord Biotech’s financial discipline and investor relations. Sethi, a seasoned chartered accountant with over three decades of experience across FMCG, chemicals, and pharmaceuticals, played a key role in Concord’s public offering and subsequent growth trajectory.  

Notable updates  
• Lalit Sethi’s early retirement effective January 5, 2026  
• Retirement attributed to personal reasons, as per company disclosure  
• Concord Biotech has initiated measures for a seamless leadership transition  
• Trading window for company securities closed for 48 hours post-announcement  
• Sethi’s tenure marked by IPO success and strong investor engagement  
• Board expected to announce succession plans shortly to reassure stakeholders  

Major takeaway  
Sethi’s departure marks a significant leadership change for Concord Biotech, a fast-growing pharmaceutical player. While his early retirement raises questions about succession, the company’s proactive transition plan and acknowledgment of his contributions signal stability and continuity for investors and employees alike.  

Sources: InvestyWise, Economic Times, LinkedIn